Survodutide
Survodutide (BI 456906)
Boehringer Ingelheim's dual-agonist targeting MASH and obesity
Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim, showing strong results for both weight loss and metabolic dysfunction-associated steatohepatitis (MASH/NASH).
Admin routes
Subcutaneous
Popularity
Niche
Side effects
Generally mild
AU vendors
0 rated
✓Key benefits
📈What to expect
Initial weight loss during dose escalation
Significant weight loss and liver enzyme improvements
~19% weight loss and potential MASH resolution
Based on community reports and published research. Individual results vary significantly.
💊Dosing protocols
Obesity/MASH (Phase 2 trial dose)
Up to 6 mg
Once weekly (subcutaneous)
Ongoing with dose escalation
Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.
Research status|Phase 2 completed for obesity and MASH; Phase 3 ongoing
Overview
Survodutide activates both GLP-1 and glucagon receptors, similar to mazdutide. What sets it apart is its clinical data in MASH (formerly NASH), the fatty liver disease affecting millions worldwide. In a Phase 2 trial, survodutide achieved MASH resolution without worsening fibrosis in up to 83% of patients at the highest dose, along with approximately 19% weight loss. The dual-agonist approach is particularly suited to liver disease because glucagon receptor activation directly promotes hepatic fat oxidation. Boehringer Ingelheim is advancing it into Phase 3 trials for both obesity and MASH.
⚙️How it works
Survodutide activates GLP-1 receptors (reducing appetite, slowing gastric emptying, improving insulin secretion) and glucagon receptors (increasing hepatic fat oxidation, boosting energy expenditure, promoting glycogenolysis). The glucagon component is what drives the liver-specific benefits: glucagon directly stimulates the liver to burn stored fat, addressing the root cause of MASH.
⚡Side effects
📅Research history
Phase 2 obesity data presented showing ~19% weight loss
MASH Phase 2 results published in NEJM: 83% resolution rate
References
- [1]Sanyal AJ, et al. 'Survodutide, a dual glucagon receptor/GLP-1 receptor agonist, for treatment of MASH.' New England Journal of Medicine, 2024.
Frequently asked questions
Related peptides
Semaglutide
Weight ManagementThe GLP-1 agonist behind the weight loss revolution
5 rated vendors
Tirzepatide
Weight ManagementThe dual-action GLP-1 that outperforms Ozempic in every trial
2 rated vendors
Retatrutide
Weight ManagementThe triple agonist showing 24% weight loss in trials
1 rated vendors
Mazdutide
Weight ManagementChina's dual-agonist obesity drug in late-stage trials
0 rated vendors
Liraglutide
Weight ManagementThe original daily GLP-1 agonist for weight and metabolic health
0 rated vendors
Community experiences
Share your experience with Survodutide. Effects, side effects, protocol details - help others make informed decisions.
No community reviews yet. Be the first to share your experience with Survodutide.
Need to calculate your dose?
Use our free reconstitution calculator to work out syringe units for Survodutide.
Open CalculatorFound this useful?
Share this guide
Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.